课题基金 / 基金详情

A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM

A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM
评估四价 HUM 免疫原性和安全性的 II 期研究
批准号:
8167119
负责人:
ARDIS A MOE
金额:
$0.53万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-01 至 2010-11-30

项目摘要

项目成果

ARDIS A MOE的其他基金

相关文献

中文摘要
翻译
该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得主要资金, 因此可以在其他CRISP条目中表示。列出的机构是 中心,不一定是研究者的机构。 确定四价HPV重组疫苗系列接种后,HPV 6、11、16和18型抗体的每个CD 4+细胞计数分层中滴度的发展高于型特异性血清阳性水平
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the development of titers in each CD4+ cell count stratum of antibodies to HPV 6, 11, 16, and 18 above a level of type-specific seropositivity after the quadrivalent HPV recombinant vaccine series
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN T
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI